title: Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: A Single-Center Experience.
abstract: OBJECTIVE
  To investigate whether balloon-occluded transcatheter arterial chemoembolization (b-TACE) can produce a more dense accumulation of iodized oil in various stages of hepatocellular carcinoma (HCC), from single to uncountable, to overcome inferior local control.
  
  
  METHODS
  We studied 27 patients with HCC, including single to uncountable multiple lesions, who underwent b-TACE between August 2013 and April 2015. Dynamic CT was performed at baseline and 1-3 months after b-TACE. The treatment effect (TE) after b-TACE was evaluated using the Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan.
  
  
  RESULTS
  In the countable HCC group, contrast-enhanced CT demonstrated RECICL TE4 in 43.8% (14/32), TE3 in 12.5% (4/32), TE2 in 37.5% (12/32), and TE1 in 6.3% (2/32) of patients. For the TACE-naïve cohort, the objective response rate was 52.9%. The objective response rate was 60% for the previously TACE-treated cohort. In the uncountable multiple HCC group, the objective response rate was 0% (0/10), with progressive disease in 90% (9/10) of patients.
  
  
  CONCLUSIONS
  Our observations suggested that b-TACE did not reduce the efficacy of retreatment for HCC with an insufficient outcome from conventional TACE, but it could not improve the efficacy of treatment for uncountable multiple HCCs.
authors.affiliation: Department of Gastroenterology and Hepatology, Faculty of Medicine, Kinki University, Osaka-Sayama, Japan.
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Minami
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Minami
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Chishina
authors.forename: Tadaaki
authors.initials: T
authors.lastname: Arizumi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Takita
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kitai
authors.forename: Norihisa
authors.initials: N
authors.lastname: Yada
authors.forename: Satoru
authors.initials: S
authors.lastname: Hagiwara
authors.forename: Masakatsu
authors.initials: M
authors.lastname: Tsurusaki
authors.forename: Yukinobu
authors.initials: Y
authors.lastname: Yagyu
authors.forename: Kazuomi
authors.initials: K
authors.lastname: Ueshima
authors.forename: Naoshi
authors.initials: N
authors.lastname: Nishida
authors.forename: Takamichi
authors.initials: T
authors.lastname: Murakami
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Kudo
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D021721:Balloon Occlusion / Q000379:methods*; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D004998:Ethiodized Oil / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008113:Liver Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D011446:Prospective Studies
chemical_list: D004998:Ethiodized Oil